Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2022 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Gains from Investment Securities came in at $84000.0 in Q1 2026, up 8300.0% YoY from $1000.0 in Q1 2025, and down 75.86% on a QoQ basis from $348000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 5 years of Gains from Investment Securities data on file, last reported at $84000.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 8300.0% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109000.0 (down 86.49% YoY) and the FY2025 annual result came in at $26000.0, down 97.0% from the prior year.
- Gains from Investment Securities declined to $84000.0 in Q1 2026, from $348000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.2 million in Q4 2024 to a low of -$1.0 million in Q4 2022.
- A 5-year average of $56352.9 and a median of $60000.0 in 2024 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities slumped 1988.89% — and 2026, when it surged 8300.0%.
- Tracing BRNS's Gains from Investment Securities over 5 years: stood at -$1.0 million in 2022, then surged by 96.95% to -$31000.0 in 2023, then jumped by 3880.65% to $1.2 million in 2024, then slumped by 70.31% to $348000.0 in 2025, then plunged by 75.86% to $84000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $84000.0 (Q1 2026), $348000.0 (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89,000.00 |
| Jun 30, 2026 | 89,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 348,000.00 |
| Dec 31, 2025 | 348,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -340,000.00 |
| Jun 30, 2025 | -340,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | -384,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Mar 31, 2024 | 60,000.00 |